Loading...
XSHE002349
Market cap796mUSD
Jan 10, Last price  
7.20CNY
1D
-4.89%
1Q
-2.44%
Jan 2017
-28.54%
IPO
113.44%
Name

Jinghua Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:002349 chart
P/E
23.58
P/S
3.86
EPS
0.31
Div Yield, %
1.13%
Shrs. gr., 5y
-0.46%
Rev. gr., 5y
2.22%
Revenues
1.51b
-3.90%
209,836,270229,554,096234,869,106259,386,550274,319,820375,502,222665,382,374732,618,193577,753,553780,334,010881,487,1701,120,920,3171,354,705,8811,157,389,4281,281,353,3241,357,868,0131,573,059,8141,511,751,346
Net income
248m
+16.71%
11,801,72125,593,43626,163,23032,799,92942,639,38648,101,77749,223,17135,597,15639,467,83878,081,130165,029,744175,319,960229,665,275027,925,069160,702,159212,225,425247,697,195
CFO
298m
-16.77%
22,181,58333,862,83917,128,89157,758,33441,059,68441,444,54977,246,691045,701,5750343,801,74275,922,62383,430,076285,382,129328,218,387305,570,854358,389,891298,300,019
Dividend
Jun 12, 20240.092 CNY/sh
Earnings
May 16, 2025

Profile

Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. Jinghua Pharmaceutical Group Co., Ltd. was founded in 1957 and is based in Nantong, China.
URL
http://www.ntjhzy.com/
IPO date
Feb 03, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,511,751
-3.90%
1,573,060
15.85%
Cost of revenue
1,002,158
1,217,331
Unusual Expense (Income)
NOPBT
509,593
355,729
NOPBT Margin
33.71%
22.61%
Operating Taxes
53,229
37,917
Tax Rate
10.45%
10.66%
NOPAT
456,364
317,812
Net income
247,697
16.71%
212,225
32.06%
Dividends
(65,984)
(48,851)
Dividend yield
0.91%
0.50%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
20,925
21,705
Long-term debt
868
1,826
Deferred revenue
10,747
10,532
Other long-term liabilities
98
122
Net debt
(1,514,850)
(1,034,689)
Cash flow
Cash from operating activities
298,300
358,390
CAPEX
(28,376)
Cash from investing activities
(219,357)
108,587
Cash from financing activities
(94,160)
FCF
377,988
798,141
Balance
Cash
1,239,454
1,058,220
Long term investments
297,189
Excess cash
1,461,055
979,567
Stockholders' equity
2,245,865
1,928,425
Invested Capital
1,375,413
1,643,938
ROIC
30.23%
17.66%
ROCE
17.92%
13.50%
EV
Common stock shares outstanding
814,258
814,181
Price
8.87
-26.57%
12.08
7.09%
Market cap
7,222,466
-26.57%
9,835,305
7.09%
EV
6,067,288
9,023,393
EBITDA
585,826
465,657
EV/EBITDA
10.36
19.38
Interest
2,838
6,794
Interest/NOPBT
0.56%
1.91%